S&P Futures
3,922.25 -49.50 (-1.25%) Dow Futures
31,584.00 -255.00 (-0.80%) Nasdaq Futures
11,805.25 -230.00 (-1.91%) Russell 2000 Futures
1,773.40 -18.40 (-1.03%) Crude Oil
108.97 -1.32 (-1.20%) Gold
1,853.10 +5.30 (+0.29%)
Cidara Therapeutics, Inc. (CDTX)
After hours:
- Benzinga
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-line treatment for candidemia and invasive candidiasis remains on track for mid-2022, which HC Wainwright takes to mean as late as August. HC Wainwright lowered the price target to $6 from $7.50, citing the challenging capi
- Zacks
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline. “We continue to advance our pipeline of Cloudbreak DFC product candidates,” said Jeffrey Stein, Ph.D., president and chief exe
